Context Therapeutics Inc. CNTX
We are a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies ("bsAb") for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 ("CLDN6") x CD3 TCE, CT-95, a Mesothelin ("MSLN") x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 ("Nectin-4") x CD3 TCE.
CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. IND-enabling studies on CTIM-76 have been completed. On May 2, 2024, we announced the U.S. Food and Drug Administration (the "FDA") cleared our IND application to support the initiation of a Phase 1 dose escalation and expansion trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. We dosed the first patient in our CTIM-76 Phase 1 trial in January 2025. We expect to share Phase 1a interim data for the CTIM-76 trial in June 2026.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| SG&A | $7.8M | $7.2M | $7.3M | $7.8M | $3.6M | $930.7K | — |
| Operating income | -$39.7M | -$29.9M | -$25.1M | -$15.4M | -$10.5M | -$2.6M | — |
| Interest expense | — | — | $1.2M | $547.3K | $64.2K | $661.2K | — |
| Pre-tax income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | -$10.5M | $6.6M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | -$10.5M | $6.6M | — |
| EPS, basic | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 | 3.07 | — |
| EPS, diluted | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 | -3.96 | — |
| Shares, diluted (wtd. avg.) | 95.2M | 58.4M | 16.0M | 16.0M | 2.8M | 2.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $66.0M | $94.4M | $14.4M | $35.5M | $49.7M | $341.0K | $226.6K |
| Total current assets | $68.4M | $97.9M | $16.0M | $37.9M | $51.3M | $299.3K | — |
| Property, plant and equipment | $29.7K | $12.0K | $15.5K | $27.6K | $0 | — | — |
| Total assets | $68.5M | $98.1M | $16.1M | $38.0M | $51.3M | $467.3K | — |
| Accounts payable | $2.5M | $1.5M | $2.4M | $936.3K | $1.8M | $2.7M | — |
| Total current liabilities | $8.0M | $2.7M | $4.2M | $3.2M | $3.0M | $9.5M | — |
| Total liabilities | $8.0M | $2.9M | $4.2M | $3.2M | $3.0M | $9.6M | — |
| Retained earnings | -$130.9M | -$94.8M | -$68.1M | -$44.1M | -$29.3M | -$18.8M | — |
| Total equity | $60.5M | $95.3M | $11.9M | $34.8M | $48.3M | -$16.9M | -$24.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.4M | -$14.6M | -$21.0M | -$13.5M | -$8.8M | -$1.0M | — |
| Depreciation and amortisation | $16.3K | $10.9K | $12.0K | $9.3K | $0 | — | — |
| Stock-based compensation | $1.3M | $841.9K | $1.1M | $976.4K | $511.1K | $219.2K | — |
| Capital expenditure | $33.9K | $7.3K | $0 | $36.8K | $0 | — | — |
| Investing cash flow | -$2.0M | -$14.8M | $0 | -$536.8K | -$250.0K | $0 | — |
| Financing cash flow | -$15.3K | $109.3M | $0 | -$102.1K | $58.4M | $1.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-020498.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |